Talking to Patients with Multiple Sclerosis About Anti-CD20 Therapies
Ahmed Obeidat, MD, PhD, and Riley Bove, MD, review strategies for how to make drug classes and the risks-benefits profiles of individual agents accessible to patients.
EP: 1.Multiple Sclerosis Disease Course and Classification
EP: 2.Defining the Utility of PIRA in Practice
EP: 3.Addressing Inflammation Upon the Diagnosis of MS
EP: 4.Multiple Sclerosis Onset and Age-Related Factors That Shape Treatment Approaches
EP: 5.Shared Decision-Making in Multiple Sclerosis Treatment
EP: 6.Clinical Trial Design and Personalized Medicine in Multiple Sclerosis
EP: 7.Customizing Treatment Approaches With High Efficacy Therapies
EP: 8.When to Stop Multiple Sclerosis Therapy
EP: 9.Immunological Phenotypes of Multiple Sclerosis and Patient Race
EP: 10.Pregnancy and Lactation in Multiple Sclerosis
EP: 11.Bladder Management and Patient-Reported Outcomes in Multiple Sclerosis Management
EP: 12.The Importance of Lifestyle Changes in Multiple Sclerosis Care
EP: 13.Anti-CD20 Therapies for MS
EP: 14.Talking to Patients with Multiple Sclerosis About Anti-CD20 Therapies
EP: 15.Safety of Anti-CD20 Therapies in Multiple Sclerosis
EP: 16.Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.
In this conversation, the speaker discusses how she presents NTCD20 therapies to patients in her practice. She emphasizes simplifying complex information and focusing on key points of efficacy and risks. She aims to empower patients by involving them in treatment decisions rather than overwhelming them with excessive material. Instead, she provides essential information such as dosing, administration methods, and considerations regarding insurance coverage. Real-world examples of patients' experiences on medication are used to illustrate the potential benefits of treatment and alleviate concerns. The speaker also acknowledges her bias towards early treatment initiation, ensuring transparency with patients about her perspective. This approach fosters informed decision-making and patient engagement in their healthcare journey.
Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.
